No Data
No Data
No Data
No Data
No Data
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs. The
BenzingaApr 22 07:00 ET
Express News | Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'
Moomoo 24/7Apr 22 07:00 ET
Express News | Plus Therapeutics Receives $3M Award Recommendation From The U.S. Department Of Defense
Moomoo 24/7Apr 22 07:00 ET
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scient
GlobeNewswireApr 9 07:00 ET
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced
GlobeNewswireMar 27 08:00 ET
Plus Therapeutics Announces Validation & Clinical Implementation Of CSF-01 Leptomeningeal Cancer Cell Diagnostic
Plus' CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeningesCSF-01 testing is used as an expl
BenzingaMar 25 08:09 ET
No Data
No Data